CONSUN PHARMA1681.HKValuation Analysis

As of Oct 16, 2026, CONSUN PHARMA (1681.HK) trades at a P/E of 9.83x, P/B of 2.40x, P/S of 3.18x, and a dividend yield of 4.98%.
Longitudinal percentile comparison: P/E sits at the 60th percentile over the trailing 10Y window (vs. 69th percentile over 3Y); P/B sits at the 78th percentile over the trailing 10Y window (vs. 73rd percentile over 3Y); P/S sits at the 79th percentile over the trailing 10Y window (vs. 72nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 71st percentile within its industry and the 45th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 6.25%, ranking at the 52nd percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 17.7 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower across the market than within its own industry — relatively cheaper next to the market as a whole. Of the 6.25% total shareholder yield, 4.98% is paid out as dividends and roughly 1.27% is implied to come from buybacks — both channels are meaningfully in play. CONSUN PHARMA operates in the Traditional Chinese Medicine Production sector. Data refreshes weekly and is for reference only, not investment advice.